drugset

drugset / Trial / NCT00840645

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

NCT00840645 ↗

Phase 3 Completed 204 enrolled Astellas Pharma Inc

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study is intended to test the safety, tolerability, and efficacy of long-term treatment with YM178 in patients with overactive bladder symptoms.

Timeline

Start: 2008-12
Primary completion: 2010-03
Completion: 2010-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirabegron	Other / unclassified	—	Oral

Indications